SCHEMBL21604950

SCHEMBL21604950

CCOC(=O)c1cnn(-c2ccnc(Cl)c2)c1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC1 P48995 2/20 0.57
TRPC3 Q13507 2/20 0.57
STIM1 Q13586 2/20 0.57
ORAI1 Q96D31 2/20 0.57
STIM2 Q9P246 2/20 0.57
MAPT P10636 5/20 0.56
HPGD P15428 8/20 0.50
ALDH1A1 P00352 8/20 0.50
KDM4E B2RXH2 6/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
GAA P10253 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
HTT P42858 1/20 0.50
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
POLB P06746 1/20 0.48
RAB9A P51151 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147804 1.00 TRPC1 (0.57) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL21604763 0.84 TRPC1 (0.64) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL2325526 0.83 MAPT (0.76) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL21605034 0.83 MAPT (0.63) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL30147963 0.83 MAPT (0.63) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL26127211 0.82 TRPC1 (0.59) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL21605077 0.81 TRPC1 (0.56) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL30147967 0.81 TRPC1 (0.56) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL21605276 0.81 TRPC1 (0.53) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL18634910 0.80 TRPC1 (0.57) TRPC1TRPC3STIM1ORAI1STIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807266-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-25 EP disclosed
EP-3807266-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-25 EP disclosed
CN-112585128-B Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2023-02-21 CN disclosed
US-11040031-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-06-22 US disclosed
US-11040031-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-06-22 US disclosed
CN-112585128-A Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2021-03-30 CN disclosed
WO-2019243964-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040031-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 TRPC1 4331/4885TRPC3 4214/4885STIM1 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.